Gene Expression in Lower Extremity Acute Traumatic Compartment Syndrome
Launched by UNIVERSITY OF UTAH · Aug 25, 2022
Trial Information
Current as of November 12, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This University of Utah study is looking at why some people with leg fractures develop acute compartment syndrome (ACS), a dangerous pressure build‑up in the leg, while others do not. Researchers will compare three groups: people with tibial shaft or tibial plateau fractures who develop ACS, people with similar fractures who do not develop ACS, and people with exertional (exercise-related) compartment syndrome who are planning surgery. They want to see if differences in genes and in the way muscle cells use their genes (gene expression) help explain who gets ACS. The main thing they will measure is myostatin, a protein related to muscle growth, to see how its activity changes in muscle from each group.
Eligible participants are adults 18 to 90 who are English-speaking and have a lower-leg fracture requiring surgery within 48 hours (with or without ACS) or people with exertional ACS about to have surgery. If you participate, a small piece of muscle from the front of the leg will be collected during your planned surgery for testing; this is in addition to your usual care and is purely for research. The study is not testing a treatment; it aims to understand genetic and muscle biology differences that may influence ACS. Enrollment is ongoing with an estimated 80 participants, and the study started in 2022, with completion planned for 2028.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient 18+ years of age. English speaking.
- • Patients with the clinical diagnosis of lower leg acute compartment syndrome secondary to tibial shaft or tibial plateau fracture.
- • Patients without clinical compartment syndrome undergoing operative intervention within 48 hours of injury for tibial shaft or tibial plateau fractures.
- • Patients with the clinical diagnosis of exertional compartment syndrome with planned surgical intervention.
- Exclusion Criteria:
- • Non-english speaking participants
About University Of Utah
The University of Utah is a prestigious research institution known for its commitment to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust infrastructure that supports a wide range of biomedical research initiatives, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies. By fostering collaboration among researchers, clinicians, and community partners, the University of Utah aims to translate scientific discoveries into effective therapies and interventions, ultimately enhancing health outcomes and contributing to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Salt Lake City, Utah, United States
Patients applied
Trial Officials
Justin Haller, M.D.
Principal Investigator
University of Utah Orthopaedics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials